A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Conditions

• Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Belantamab mafodotin — DRUG
  Belantamab mafodotin will be administered.
• Dexamethasone — DRUG
  Dexamethasone will be administered.
• Pomalidomide — DRUG
  Pomalidomide will be administered.
• Bortezomib — DRUG
  Bortezomib will be administered.
• Carfilzomib — DRUG
  Carfilzomib will be administered.

Study Details

This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.

Key Dates

Start date

Apr 15, 2026

Status verified

Jun 2026

Primary completion

Aug 30, 2030

Completion

Aug 30, 2030

Study Design

Enrollment

200 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Belantamab mafodotin + Pomalidomide + Dexamethasone (BPd)
• Experimental: Belantamab mafodotin + Bortezomib + Dexamethasone (BVd)
• Experimental: Belantamab mafodotin + Carfilzomib + dexamethasone (BKd)

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Up to approximately 52 months ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (9)

Find similar trials in Los Alamitos, CA

Related Studies

• Collection of Tissue Samples for Cancer Research
  Recruiting · National Cancer Institute (NCI) · Sacramento, California
• Tissue Collection for Studies of Lymph Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
  Enrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland